Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?
European Journal of Cancer · 2026-11 · 248 · 117064
DOI: 10.1016/j.ejca.2026.117064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Vitor T Liutti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hospital do Câncer de Londrina, Londrina, Brazil. Electronic address: vtliutti@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital do Câncer de Londrina, Londrina, Brazil. Electronic address: vtliutti@gmail.com.
- Universitair Ziekenhuis Leuven, Leuven, Belgium. Electronic address: hans.wildiers@uzleuven.be.
- Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, the Netherlands. Electronic address: g.sonke@nki.nl.
- Universitair Ziekenhuis Leuven, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.
Zitieren
APA
Liutti, V. T., Wildiers, H., Sonke, G. S., & Neven, P. (2026). Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?. European Journal of Cancer, 248, 117064. https://doi.org/10.1016/j.ejca.2026.117064
Vancouver
Liutti VT, Wildiers H, Sonke GS, Neven P. Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?. European Journal of Cancer. 2026;248:117064. doi:10.1016/j.ejca.2026.117064
BibTeX
@article{Liutti2026,
author = {Liutti, Vitor T and Wildiers, Hans and Sonke, Gabe S and Neven, Patrick},
title = {Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117064},
doi = {10.1016/j.ejca.2026.117064}
}
EUVIMED